Janssen Applys to EMA to Expand Use of Imbruvica
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…
Pharmaceuticals, Biotechnology and Life Sciences
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…
OptiBiotix Health has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.
Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement.
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.
Eli Lilly and Company has revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana.
A single variation in the gene for brain-derived neurotropic factor (BDNF) may influence obesity in children and adults, according to a new study funded by the National Institutes of Health.
Eylea is now also approved for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV).
United States Food and Drug Administration (FDA) has approved Lonsurf (trifluridine and tipiracil) tablets for the treatment of patients with metastatic colorectal cancer who have been previously…
Allergan plc has confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction.